Abstract:ID 90311 Poster Board 475 The D 2 dopamine receptor (D2R) is a G protein-coupled receptor (GPCR) and a validated drug target for the treatment of many neuropsychiatric disorders, including psychosis. All currently available antipsychotics are antagonists of the D2R; however, all of these drugs exhibit polypharmacology resulting in a plethora of off-target side effects including weight gain, dysphoria, and sedation, among others. A highly-selective D2R antagonist might overcome these pitfalls and increase patient compliance with taking antipsychotic medications. Previously, our lab conducted a high-throughput screen to identify D2R-selective antagonists with reduced activity at other GPCRs. This screen identified a promising hit compound that was chemically optimized into the lead drug candidates, NCGC1360 and NCGC1366. These drug leads have relatively high binding affinities at the D2R (~80 and ~50 nM, respectively), while displaying >100-fold selectivity over the D3R and >24-fold selectivity over the D4R. A β-arrestin recruitment assay revealed even higher D2R selectivity (>100-fold) of these compounds over the D3R and D4R. In a screen against an array of 46 GPCRs, channels, and transporters using radioligand binding assays, NCGC1360 and NCGC1366 only inhibited radioligand binding to the D2R. A functional screen of 168 GPCRs further determined that NCGC1360 and NCGC1366 were exceptionally selective with each compound completely antagonizing β-arrestin recruitment to the D2R with only minor effects at a few other receptors. Schild-type analyses using dopamine-stimulated β-arrestin recruitment revealed that both compounds are competitive antagonists. A comparative molecular docking study using the active structures of both the D2R and D3R showed that NCGC1366 occupies the orthosteric binding pocket of the D2R with extended contacts with residues in extracellular loop 2 (ECL2). The contacts in ECL2 are not conserved between the D2R and D3R, which may confer D2R selectivity. We thus swapped the ECL2 of the D2R and D3R and found that a D2R mutant with the D3R ECL2 exhibited diminished affinity for NCGC1360 and NCGC1366. Conversely, a D3R mutant with the D2R ECL2 exhibited increased affinity for NCGC1360 and NCGC1366, consistent with the molecular docking study. Pharmacokinetic studies of NCGC1360 in mice revealed a half-life of 1.8 hr in plasma and 1 hr in brain with excellent brain penetration. Finally, NCGC1360 was characterized in animal models that are predicative of antipsychotic efficacy and on-target side effects. NCGC1360 dose-dependently decreased amphetamine-induced hyperlocomotion in mice and also rescued deficits in pre-pulse inhibition induced by amphetamine. Importantly, NCGC1360 did not induce catalepsy up to the highest dose tested (10 mg/kg), suggesting that it would not induce extrapyramidal side effects in patients. Taken together, these studies provide support for continuing the development of this scaffold with preclinical and IND-enabling studies. Funded by the National Institutes of Health intramural research program.

SK609, a novel dopamine D3 receptor agonist and norepinephrine transporter blocker with putative pro-cognitive actions, does not induce psychostimulant-like increases in risky choice during probabilistic discounting

SK609, a novel dopamine D3 receptor agonist and norepinephrine transporter blocker with pro-cognitive actions, does not induce psychostimulant-like increases in risky choice during probabilistic discounting

Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia

Potentiation of prefrontal cortex dopamine function by the novel cognitive enhancer d-govadine

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

Methylphenidate (‘ritalin’) Can Ameliorate Abnormal Risk-Taking Behavior in the Frontal Variant of Frontotemporal Dementia

Dopamine Release in Dissociable Striatal Subregions Predicts the Different Effects of Oral Methylphenidate on Reversal Learning and Spatial Working Memory

A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions

A Dopamine D1 Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory

Modulation of High Impulsivity and Attentional Performance in Rats by Selective Direct and Indirect Dopaminergic and Noradrenergic Receptor Agonists

SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action

Enhanced cognitive flexibility and phasic striatal dopamine dynamics in a mouse model of low striatal tonic dopamine

Characterization of NCGC1360 and NCGC1366 as Highly-Selective D2 Dopamine Receptor Antagonists and Lead Candidates for the Treatment of Neuropsychiatric Disorders

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Methylphenidate, but not citalopram, decreases impulsive choice in rats performing a temporal discounting task

Norepinephrine and Dopamine Modulate Impulsivity on the Five-Choice Serial Reaction Time Task Through Opponent Actions in the Shell and Core Sub-Regions of the Nucleus Accumbens

The neuropharmacological properties of α-pyrrolidinobutiothiophenone, a new synthetic cathinone, in rodents; role of the dopaminergic system

Methylphenidate-induced Impulsivity: Pharmacological Antagonism by Β-Adrenoreceptor Blockade

Biased Signaling Agonists Promote Distinct Phosphorylation and Conformational States of the Dopamine D3 Receptor

In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

SKF82958, a dopamine D1 receptor agonist, disrupts prepulse inhibition in the medial prefrontal cortex and nucleus accumbens in C57BL/6J mice